title: Outcomes in the Guillain Barre syndrome: the role of steroids.
abstract: Guillain-Barre Syndrome (GBS) is one of the commonest demyelinating diseases of the peripheral nervous system. This retrospective cohort study reports the outcomes of 97 patients in a large teaching hospital in South India. Fifty patients were treated with steroids and 47 had no steroids. Twenty one of the 41 evaluable patients in the steroid group had functional improvement at discharge as compared to 20 of 42 evaluable patients in the non-steroid group. Six patients in each group had worsening of their weakness. Steroids did not show any significant beneficial effect in either improving the disability scores at discharge (steroid-0.42 vs. non-steroid-0.29) or in reducing the duration of ICU stay (4 vs. 8 median days). A higher proportion of patients on steroids developed complications (p = 0.02). The median duration of hospital stay was 16 days in the steroid group as opposed to 14 days in the group not treated with steroids. The mortality was 6 in the steroid treated group and 5 in the non-steroid group. Steroids have no significant benefit on the outcome of GBS.
authors.affiliation: Department (Medicine), Christian Medical College and Hospital, Vellore.
authors.forename: J V
authors.initials: JV
authors.lastname: Peter
authors.forename: C
authors.initials: C
authors.lastname: Gnanamuthu
authors.forename: A M
authors.initials: AM
authors.lastname: Cherian
authors.forename: S
authors.initials: S
authors.lastname: Prabhakar
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D015331:Cohort Studies; D003907:Dexamethasone / Q000627:therapeutic use*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007194:India / Q000453:epidemiology; D008297:Male; D011129:Polyradiculoneuropathy / Q000188:drug therapy* / Q000453:epidemiology; D011239:Prednisolone / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D005938:Glucocorticoids; D003907:Dexamethasone; D011239:Prednisolone